Africa lacks preparedness for virus vaccine rollout – WHO

Agence France-Presse

This is AI generated summarization, which may have errors. For context, always refer to the full article.

MASKED. South Africa during the COVID-19 pandemic

AFP photo

The main concerns are a lack of adequate funding plans, monitoring tools, and community outreach

The World Health Organization on Thursday, November 26, urged African countries to improve their capacity to vaccinate populations against COVID-19, warning the continent was still “far from ready” for mass immunization.

With 3 coronavirus vaccines now showing efficacy rates of 70% or more, the UN body called on Africa to “ramp up” preparations for “the continent’s largest ever immunization drive.”

The African region is so far only 33% ready to roll out COVID-19 vaccines, the World Health Organization (WHO) said in a statement.

That figure, based on data provided by 40 countries on a series of “readiness criteria,” is well below a desired 80% benchmark.

“Planning and preparation will make or break this unprecedented endeavor,” WHO Africa Director Matshidiso Moeti said during a virtual press briefing.

The main concerns are a lack of adequate funding plans, monitoring tools, and community outreach.

“There are key logistical and financing gaps where international solidarity will be imperative,” Moeti said.

The WHO estimates that rolling out a COVID-19 vaccine to just priority populations in Africa will cost around $5.7 billion (4.8 billion euros).

African countries will be partially subsidized by the COVAX global COVID-19 distribution scheme.

The World Bank has also set aside $12 billion (10.1 billion euros) to help developing countries finance their immunization programs.

Moeti said the aim was to vaccinate 3% of Africa’s population by March 2021, and 20% by the end of the year.

Must Read

Philippines aims to vaccinate 60M-70M people in 3 to 5 years

Philippines aims to vaccinate 60M-70M people in 3 to 5 years
Africa-based research

Other health experts at the briefing said additional research was needed to develop vaccines more suitable to the continent. 

They noted that a promising vaccine developed by Pfizer and BioNTech, which tested at a 95% success rate at its latest trial, must be kept at -70 degrees celsius – all but impossible for most hospitals in Africa.

“We really should be doing some of this vaccine research in the African region,” said Helen Rees, chair of the WHO’s Africa immunization advisory group.

So far only Egypt, Morocco, Kenya, and South Africa have active COVID-19 vaccine trials.

Moeti said it was important for the continent not to fall behind on global preparations for COVID-19 vaccinations even though coronavirus infections had somewhat plateaued.

She noted that Africa has been relatively spared compared to the rest of the world, with over 2.1 million cases and 50,000 deaths recorded to date.

But some countries are beginning to see localized infection surges, particularly in South Africa and the Maghreb.

“We are starting to see an uptick and that gives us a lot of concern,” Moeti warned. “The curve is once again trending upwards a little bit.”

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.

Summarize this article with AI

How does this make you feel?

Download the Rappler App!